The Transformative Role of Contrast-Enhanced Ultrasound (CEUS) in Chronic Liver Disease

Dear Colleagues,

Managing the complex journey of chronic liver disease (CLD), from cirrhosis to hepatocellular carcinoma (HCC) and transplatation, demands imaging that is precise, safe, accessible, and adaptable. Contrast-Enhanced Ultrasound (CEUS) has emerged as a revolutionary tool, offering, for the first time, real-time, dynamic visualization of liver microvascularity without ionizing radiation or nephrotoxic risk. Its compelling clinical utility spans the entire spectrum of CLD care. Diagnosis: CEUS excels in characterizing elusive focal liver lesions. By capturing unique, real-time enhancement patterns, it achieves high diagnostic accuracy (sensitivity 85-92%, specificity 89-95%) for HCC within cirrhotic livers, frequently matching CT/MRI. It crucially clarifies indeterminate lesions found on baseline US, reducing diagnostic delays and unnecessary invasive procedures. Follow-up and Monitoring: CEUS shines in longitudinal surveillance. Its real-time nature makes it exceptionally sensitive for detecting residual or recurrent tumor post-ablation and monitoring treatment response. It effectively identifies critical complications like portal vein thrombosis. Its outstanding safety profile allows for frequent, repeat examinations, making it ideal for patients with renal impairment where CT/MRI contrast is contraindicated. Therapy Guidance: CEUS becomes an invaluable intra-procedural partner. It dramatically enhances the precision and safety of biopsies and ablations by confirming target viability and spatial relationships to vessels in real-time, boosting diagnostic yield, ensuring complete ablation, and minimizing complications.

Why CEUS is indispensable? It delivers diagnostic performance rivaling advanced cross-sectional imaging but with unparalleled safety, lower cost, true real-time dynamic assessment, and point-of-care convenience. CEUS is not merely an alternative; it is an essential, versatile tool that enhances diagnostic confidence, optimizes therapeutic precision, and enables safe, personalized monitoring throughout the CLD pathway.

The growing body of evidence solidifying CEUS's pivotal role invites further exploration. We encourage researchers and clinicians to contribute original research articles, comprehensive reviews, and insightful case studies focusing on CEUS applications in CLD diagnosis, innovative follow-up strategies, therapeutic guidance, and future directions. Share your expertise to advance best practices and solidify CEUS's position in modern hepatology.

Dr. Francesco Giangregorio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.